Effect of Desipramine on Upper Airway Collapsibility and Genioglossus Muscle Activity in Patients With Obstructive Sleep Apnea - Study B

The requested reference [1d5b89d42819f3c0096f4f2781ebb835d6eab224] no longer exists in our database. It has been replaced by the current reference: [f6f43902fb9fb70a1ebd04c205a6ed2ae91fe06a]

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal participants. Until recently, the search for medicines to activate pharyngeal muscles in sleeping humans has been discouraging. However, exciting new animal research has shown that drugs with noradrenergic and antimuscarinic effects can restore pharyngeal muscle activity to waking levels. In this protocol the investigators will test the effect of desipramine (a tricyclic antidepressant with strong noradrenergic and antimuscarinic effects) on upper airway collapsibility and genioglossus muscle activity (EMG GG) during sleep in OSA patients.
Epistemonikos ID: 962e72e90615d4453f1dd9093df7a66fa6ba0865
First added on: May 12, 2024